POLAR NANOPHARMA
Contact information
- Biodrugs
- Drug delivery
- Drug development
- Drug discovery
- Gene Therapy
- Biomaterials and tissue therapy
- Vaccines
- Oncology
- Monomers and polymers
- Chemistry
- Consultancy
- CRO / CMO / SMO
Polar NanoPharma is a spin-out of Ecopol Tech developing advanced drug delivery solutions for oncology, with a focus on the treatment of solid tumors. Its mission is to transform anticancer drugs limited by toxicity, poor solubility or suboptimal biodistribution into safer, more effective and more selective therapies. The company leverages ECOSTRATAR, a versatile, modular and highly stable polymeric encapsulation technology based on biocompatible multifunctional polycarbamate-polyurea polymers. Its goal is to accelerate the development of oncology nanomedicines with strong clinical, pharmaceutical and industrial potential.
Polar NanoPharma develops oncology nanomedicines based on ECOSTRATAR, its polymeric nanoparticle platform for the encapsulation, protection and controlled release of anticancer drugs. The technology enables the formulation of cytotoxic agents, immunomodulators and other therapeutic molecules, aiming to improve their solubility, stability, biodistribution, therapeutic efficacy and safety profile.
The company combines the development of proprietary oncology therapeutic candidates with advanced formulation services for third parties, including polymer selection, nanoparticle optimization, physicochemical characterization, stability studies, early preclinical validation and support for co-development, licensing and technology transfer strategies.
Oncology, nanomedicine, drug delivery / controlled drug release, novel formulations of anticancer therapies, combination therapies in cancer, immuno-oncology, advanced therapies, and preclinical and clinical development of nanotherapies.